Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth

Evotec SE, a German drug discovery powerhouse, continues to advance partnerships with major US pharma firms, positioning it as a key player for American investors tracking biotech innovation pipelines.

Evotec SE maintains its role as a leading contract research organization in drug discovery, recently highlighted for ongoing collaborations that support US pharmaceutical giants. The company reported steady progress in its pipeline during its fiscal year 2025 results published on March 27, 2026, according to Evotec IR as of 03/27/2026. Shares traded at approximately 8.50 EUR on Xetra on May 13, 2026, reflecting stability amid biotech sector volatility.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology / Drug Discovery
• Headquarters/country: Hamburg, Germany
• Core markets: US, Europe
• Key revenue drivers: Partnerships, milestones, royalties
• Home exchange/listing venue: Xetra (EVT)
• Trading currency: EUR

Evotec SE: core business model

Evotec SE operates an integrated drug discovery and development platform, partnering with pharmaceutical and biotech companies to advance novel therapies from target identification to clinical stages. Headquartered in Hamburg, the firm employs over 5,000 scientists across sites in Europe and the US, focusing on high-throughput screening, AI-driven chemistry, and translational research. This asset-agnostic model allows Evotec to share risks and rewards through milestones and royalties, as outlined in its 2025 annual report published March 27, 2026, per Evotec IR as of 03/27/2026.

The company's EVT Execute division provides end-to-end services, while EVT Innovate builds proprietary assets for co-development. Key US exposure comes from facilities in Princeton, New Jersey, and collaborations with firms like Bristol Myers Squibb and Janssen, making Evotec relevant for US investors seeking outsourced R&D plays.

Main revenue and product drivers for Evotec SE

Evotec generates revenue primarily from collaboration agreements, with 2025 group revenues reaching €751.6 million, up 4% at constant exchange rates from the prior year, according to the annual report released March 27, 2026, via Evotec IR as of 03/27/2026. Milestones and upfront payments accounted for a significant portion, alongside royalties from approved drugs like those in oncology and neurology.

Strategic partnerships drive growth, including a multi-year deal with Sanofi extended in 2025, contributing to pipeline advancements. For US investors, Evotec's role in US-centric programs, such as those targeting metabolic diseases, underscores its exposure to the world's largest pharma market.

Industry trends and competitive position

The biotech services sector benefits from Big Pharma's shift toward external innovation, with CRO spending projected to grow 8% annually through 2030, per IQVIA data published January 2026. Evotec differentiates through its AI platforms like Omics and high-content screening, positioning it against competitors like Charles River Laboratories and WuXi AppTec.

In the US, where over 50% of global drug approvals occur, Evotec's North American footprint enhances its competitive edge, serving clients amid rising demand for faster discovery timelines.

Why Evotec SE matters for US investors

Evotec SE offers US investors indirect exposure to biotech innovation without single-asset risk, leveraging partnerships with NYSE-listed giants. Its US sites and dollar-denominated contracts provide currency diversification, while Nasdaq biotech volatility amplifies interest in stable service providers like Evotec.

Conclusion

Evotec SE remains a cornerstone in drug discovery outsourcing, with solid 2025 results and a robust partnership portfolio supporting long-term potential. US investors may note its strategic US presence amid ongoing pipeline milestones. Market dynamics will continue shaping its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.